The role of 18F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited

Hellenic Journal of Nuclear Medicine

Volumn 17, Issue 3, 2014, Pages 177-183

  Zhang, Xuemei ^a   Wu, Fengyu ^b   Han, Ping ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

18F FDG PET; Axillary lymph nodes; Distal metastases; Micrometastases

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; BREAST NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84919968359     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fan L, Strasser-Weippl K, Li JJ et al. Breast cancer in China. Lancet Oncol 2014; 15(7): e279-89.
2. Yutani K, Shiba E, Kusuoka H et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000; 24(2): 274-80.
3. Groheux D, Giacchetti S, Delord M et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 2013; 54(1): 5-11.
4. Schirrmeister H, Kühn T, Guhlmann A et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28(3): 351-8.
5. Wahl RL, Siegel BA, Coleman RE et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 277-85.
6. Guller U, Nitzsche EU, Schirp U et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet. Breast Cancer Res Treat 2002; 71: 171-3.
7. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002; 3: 73-7.
8. Veronesi U, De Cicco C, Galimberti VE et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18: 473-8.
9. Taira N, Ohsumi S, Takabatake D et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol 2009; 39(1): 16-21.
10. Walter W, Scheidhauer K, Scharl A et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003; 13(7): 1651-6.
11. Heinsich M, Gallowitsch HJ, Mikosch P et al. Comparison of FDG-PET and dynamic contrastenhanced RM in the evaluation of suggestive breast lesions. Breast 2003; 12(1): 17-22.
12. Rieber A, Schirrmeister H, Gabelmann A et al. Pre-operative staging of invasive breast cancer with MR mammography and/or FDG-PET: boon or bunk? Br J Radiol 2002; 75(898): 789-98.
13. Marshall C, Mustafa S, Wheatley DC et al. A comparison of 18F-FDG gamma camera PET, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer. Nucl Med Commun 2004; 25(7): 721-5.
14. 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18FFDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008; 8: 165.
15. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47(1): 170-5.
16. Fortin A, Larochelle M, Laverdière J et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999; 17: 101-9.
17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6): 1471-4.
18. Rong J, Wang S, Ding Q et al. Comparison of 18 FDG PET/CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 2013; 22(2): 86-91.
19. Kumar R, Chauhan A, Zhuang H et al. Clinicopathologic factors associated with false negative FDG PET in primary breast cancer. Breast Cancer Res Treat 2006; 98(3): 267-74.
20. 18-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75(2): 135-46.
21. Uematsu T, Kasami M, Yuen S. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are can didates for breast-conserving therapy. Breast Cancer 2009; 16(2): 97-104.
22. Escalona S1, Blasco JA, Reza MM et al. A systematic review of FDG-PET in breast cancer. Med Oncol 2010; 27(1): 114-29.
23. Vidal-Sicart S1, Aukema TS, Vogel WV et al. Added value of prone position technique for PET-TAC in breast cancer patients. Rev Esp Med Nucl 2010; 29(5): 230-5.
24. Carkaci S, Adrada BE, Rohren E et al. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differ entiating benign from malignant? Acad Radiol 2012; 19(5): 535-41.
25. 18-FDG PET/CT for Detecting Axillary Lymph Node Metastasis in T1 Breast Cancer. J Breast Cancer 2013; 16(3): 315-21.
26. Robertson IJ1, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast 2011; 20(6): 491-4.
27. Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and metaanalysis of the literature. Breast Cancer Res Treat 2010; 123(1): 281-90.
28. Greco M, Crippa F, Agresti R et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission to mography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93(8): 630-5.
29. Zornoza G, Garcia-Velloso MJ, Sola J et al. 18 F-FDG PET comple mented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004; 30(1): 15-9.
30. Avril N, Dose J, Jänicke F et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14(6): 1848-57.
31. Raylman RR, Kison PV, Wahl RL. Capabilities of two- and three-di mensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: A dynamic phantom study. Eur J Nucl Med 1999; 26: 39-45.
32. Vranjesevic D, Filmont JE, Meta J et al. Whole-body 18F-FDG FDGPET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43(3): 325-9.
33. van der Hoeven JJ, Hoekstra OS, Comans EF et al. Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002; 236: 619-24.
34. 18-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer. Nucl Med Mol Imaging 2010; 44(3): 170-6.
35. Bellevre D, Blanc Fournier C, Switsers O et al. Staging the axilla in breast cancer patients with 1 8F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? Eur J Nucl Med Mol Imaging 2014; 41(6): 1103-12.
36. Seo MJ, Lee JJ, Kim HO et al. Detection of internal mammary lymph node metastasis with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer. Eur J Nucl Med Mol Imaging 2014; 41(3): 438-45.
37. 18-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer. Acta Radiol 2014; Nov. 18, pii: 0284185114556929. [Epub ahead of print].
38. Langer I, Marti WR, Guller U et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN mi crometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241(1): 152-8.
39. Reed J, Rosman M, Verbanac KM et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients en rolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009; 208(3): 333-40.